|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Royal (Dick) School of Veterinary Studies, The Roslin Institute, University of Edinburgh, Roslin, Midlothian, Edinburgh EH25 9PS, UK
2 MRC Human Reproductive Sciences Unit, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK
3 MRC/UCT, Group for Receptor Biology, University of Cape Town, Cape Town 7925, South Africa
(Correspondence should be addressed to N T Joseph; Email: nerine.joseph{at}bbsrc.ac.uk)
This is an Open Access article distributed under the terms of the Society for Endocrinology's Re-use Licence which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
1400-fold more abundant than cGnRH-R-I mRNA. Northern analysis indicated a single cGnRH-R-III transcript. A pronounced sex and age difference existed, with higher pituitary transcript levels in sexually mature females versus juvenile females. In contrast, higher expression levels occurred in juvenile males versus sexually mature males. Functional studies in COS-7 cells indicated that cGnRH-R-III has a higher binding affinity for GnRH-II than cGnRH-I (Kd: 0.57 vs 19.8 nM) with more potent stimulation of inositol phosphate production (ED50: 0.8 vs 4.38 nM). Similar results were found for cGnRH-R-I, (Kd: 0.51 vs 10.8 nM) and (ED50: 0.7 vs 2.8 nM). The initial rate of internalisation was faster for cGnRH-R-III than cGnRH-R-I (26 vs 15.8%/min). Effects of GnRH antagonists were compared at the two receptors. Antagonist #27 distinguished between cGnRH-R-I and cGnRH-R-III (IC50: 2.3 vs 351 nM). These results suggest that cGnRH-R-III is probably the major mediator of pituitary gonadotroph function, that antagonist #27 may allow delineation of receptor subtype function in vitro and in vivo and that tissue-specific recruitment of cGnRH-R isoforms has occurred during evolution.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |